Show simple item record

dc.contributor.authorWidmer, M
dc.contributor.authorPiaggio, G
dc.contributor.authorNguyen, TM
dc.contributor.authorOsoti, A
dc.contributor.authorOwa, O
dc.contributor.authorMisra, S
dc.contributor.authorCoomarasamy, A
dc.contributor.authorAbdel-Aleem, H
dc.contributor.authorMallapur, A
dc.contributor.authorQureshi, Z
dc.contributor.authorLumbiganon, P
dc.contributor.authorPatel, AB
dc.contributor.authorCarroli, G
dc.contributor.authorFawole, B
dc.contributor.authorGoudar, SS
dc.contributor.authorPujar, YV
dc.contributor.authorNeilson, J
dc.contributor.authorHofmeyr, GJ
dc.contributor.authorSu, LL
dc.contributor.authorFerreira de Carvalho, J
dc.contributor.authorPandey, U
dc.contributor.authorMugerwa, K
dc.contributor.authorShiragur, SS
dc.contributor.authorByamugisha, J
dc.contributor.authorGiordano, D
dc.contributor.authorGülmezoglu, AM
dc.description.abstractBackground Postpartum hemorrhage is the most common cause of maternal death. Oxytocin is the standard therapy for the prevention of postpartum hemorrhage, but it requires cold storage, which is not available in many countries. In a large trial, we compared a novel formulation of heat-stable carbetocin with oxytocin. Methods We enrolled women across 23 sites in 10 countries in a randomized, double-blind, noninferiority trial comparing intramuscular injections of heat-stable carbetocin (at a dose of 100 μg) with oxytocin (at a dose of 10 IU) administered immediately after vaginal birth. Both drugs were kept in cold storage (2 to 8°C) to maintain double-blinding. There were two primary outcomes: the proportion of women with blood loss of at least 500 ml or the use of additional uterotonic agents, and the proportion of women with blood loss of at least 1000 ml. The noninferiority margins for the relative risks of these outcomes were 1.16 and 1.23, respectively. Results A total of 29,645 women underwent randomization. The frequency of blood loss of at least 500 ml or the use of additional uterotonic agents was 14.5% in the carbetocin group and 14.4% in the oxytocin group (relative risk, 1.01; 95% confidence interval [CI], 0.95 to 1.06), a finding that was consistent with noninferiority. The frequency of blood loss of at least 1000 ml was 1.51% in the carbetocin group and 1.45% in the oxytocin group (relative risk, 1.04; 95% CI, 0.87 to 1.25), with the confidence interval crossing the margin of noninferiority. The use of additional uterotonic agents, interventions to stop bleeding, and adverse effects did not differ significantly between the two groups. Conclusions Heat-stable carbetocin was noninferior to oxytocin for the prevention of blood loss of at least 500 ml or the use of additional uterotonic agents. Noninferiority was not shown for the outcome of blood loss of at least 1000 ml; low event rates for this outcome reduced the power of the trial. (Funded by Merck Sharpe & Dohme; CHAMPION Australian New Zealand Clinical Trials Registry number, ACTRN12614000870651 ; EudraCT number, 2014-004445-26 ; and Clinical Trials Registry-India number, CTRI/2016/05/006969 .).en_US
dc.publisherUniversity of Nairobien_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.titleHeat-Stable Carbetocin versus Oxytocin to Prevent Hemorrhage after Vaginal Birth.en_US

Files in this item


There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivs 3.0 United States
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States